Simulations Plus, Inc. (SLP) Stock Price
SLPStock
$18.50+15.48%52W
Market Cap$374.16M
P/E—
PEG Ratio9.88
Div yield0.61%
Beta1.21
SLP Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)37.37%
Price vs S&P 500 (4W)-0.72%
PEG Ratio9.88
VGM Score51.54
Indicated Dividend Yield (Annual)0.61%
SLP Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $0.23 | $0.30 | +29.03%(+$0.07) | |
| Q1 2026 | $0.30 | $0.35 | +14.75%(+$0.04) | |
| Q4 2025 | $0.20 | $0.13 | -34.06%(-$0.07) | |
| Q3 2025 | $0.12 | $0.10 | -19.35%(-$0.02) |
SLP Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
3.82
2.50
2.50
2.50
Industry Peers — Computer Integrated Systems(65)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
SLPSimulations Plus, Inc. | D | C | B | 4.6x | 2.1% | 63.4% | 14.0% | $18.50 |
| IOTSamsara Inc. | F | A | B | 12.5x | 29.5% | 76.4% | 1.1% | $39.57 |
| LDOSLeidos Holdings, Inc. | B | C | B | 0.9x | 3.4% | 17.8% | 11.4% | $124.85 |
| CACICACI INTERNATIONAL CLA | C | C | B | 1.4x | 10.9% | 33.2% | 9.6% | $614.31 |
| GDDYGoDaddy Inc | C | C | B | 2.6x | 7.4% | 63.8% | 24.8% | $105.96 |
| IONQIonQ, Inc. | F | A | D | 51.4x | 370.6% | 30.9% | -408.2% | $31.28 |
| JKHYHenry (Jack) & Associates | C | C | B | 4.2x | 7.1% | 43.6% | 25.0% | $153.19 |
| AURAurora Innovation, Inc. Class A Common Stock | F | A | C | 1946.0x | — | -400.0% | -19400.0% | $4.86 |
| QNTQuantinuum Inc. Class A Common Stock | — | F | D | 217.9x | — | 63.4% | -1882.6% | $36.55 |
| OTEXOpen Text Corp | B | C | B | 1.2x | 1.5% | 73.7% | 21.7% | $25.50 |
| SAICScience Applications International Corporation Common Stock | B | D | A | 0.8x | -0.8% | 12.7% | 8.0% | $133.07 |
About Simulations Plus, Inc.
Simulations Plus develops software for pharmaceutical research and drug development, with its flagship ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) modeling platform serving a core use case in early-stage drug testing. The company generates revenue primarily through software sales, supplemented by consulting and contract research services for pharmaceutical clients. Geographic revenue is concentrated in the United States, with secondary markets in EMEA and Asia Pacific.